SII and SIRI as Prognostic Biomarkers in Lupus Nephritis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorAssiut University
About this trial
This prospective observational study aims to evaluate the prognostic utility of the Systemic Immune-Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI) as novel inflammatory biomarkers for monitoring disease activity and predicting renal progression, flares, and outcomes in patients with lupus nephritis.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Diagnosis of systemic lupus erythematosus according to the 2019 EULAR/ACR classification criteria
Confirmed lupus nephritis according to ISN/RPS classification
Disqualifiers
Active infection, sepsis, or other concurrent inflammatory or autoimmune conditions
Malignancy or hematologic disorders affecting blood cell counts
Pregnancy
Use of medications significantly affecting blood counts (such as recent chemotherapy or G-CSF)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov